# Insulet

Type: Company (PODD)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/insulet
Canonical HTML page: https://getbiobrief.com/entity/insulet

## Timeline

- **2026-03-06**: IPO Pricing — MiniMed prices 28 million shares at $20.00 per share, raising $560 million.
- **2026-03-04**: Analyst Debate — Market analysts debate the valuation of the diabetes unit amid competitive pressures.
- **2026-02-24**: Initial Filing — Medtronic's diabetes unit MiniMed seeks up to $784 million in U.S. IPO.

## Recent coverage (2 stories)

### Medtronic’s MiniMed Prices IPO at $20 Per Share, Raising $560 Million
2026-03-06 03:34:10 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Medtronic’s diabetes subsidiary, MiniMed Group Inc., has priced its initial public offering at $20.00 per share, successfully raising $560 million. The offering of 28 million shares comes in below initial valuation targets but marks a significant strategic pivot for parent company Medtronic plc.
Full story: https://getbiobrief.com/story/medtronic-minimed-ipo-pricing-analysis

### MedTech Resilience: Insulet and AtriCure Outperform Q4 Earnings Expectations
2026-02-18 19:19:07 · Sentiment: Positive · Impact: 6/10 · Sources: 6

Insulet and AtriCure reported strong quarterly results, both beating analyst estimates on top and bottom lines. These results highlight robust demand for insulin delivery systems and atrial fibrillation treatments despite broader macroeconomic pressures.
Full story: https://getbiobrief.com/story/medtech-earnings-insulet-atricure-q4-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.